Phreesia, Inc. (NYSE:PHR – Get Free Report) SVP David Linetsky sold 11,685 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $27.48, for a total value of $321,103.80. Following the completion of the sale, the senior vice president now owns 231,271 shares of the company’s stock, valued at approximately $6,355,327.08. This represents a 4.81 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
David Linetsky also recently made the following trade(s):
- On Wednesday, December 18th, David Linetsky sold 24 shares of Phreesia stock. The shares were sold at an average price of $25.38, for a total transaction of $609.12.
- On Monday, December 16th, David Linetsky sold 35 shares of Phreesia stock. The stock was sold at an average price of $24.88, for a total transaction of $870.80.
- On Wednesday, December 11th, David Linetsky sold 11,853 shares of Phreesia stock. The shares were sold at an average price of $24.85, for a total transaction of $294,547.05.
Phreesia Trading Up 1.1 %
Shares of Phreesia stock opened at $29.03 on Friday. The company has a 50-day moving average of $24.78 and a two-hundred day moving average of $23.24. The stock has a market cap of $1.69 billion, a PE ratio of -19.75 and a beta of 0.94. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.90.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. JMP Securities restated a “market outperform” rating and issued a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and boosted their target price for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Phreesia in a report on Friday, January 10th. Robert W. Baird dropped their price objective on shares of Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Finally, Piper Sandler restated an “overweight” rating and issued a $33.00 target price (up previously from $31.00) on shares of Phreesia in a research note on Wednesday. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.15.
Get Our Latest Stock Analysis on Phreesia
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the company. Trust Point Inc. increased its holdings in Phreesia by 3.5% during the 3rd quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock valued at $408,000 after acquiring an additional 607 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Phreesia by 3.3% in the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after purchasing an additional 905 shares during the last quarter. MetLife Investment Management LLC increased its stake in shares of Phreesia by 3.8% during the 3rd quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock worth $701,000 after purchasing an additional 1,120 shares in the last quarter. R Squared Ltd acquired a new position in shares of Phreesia during the 4th quarter worth approximately $30,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Phreesia by 9.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company’s stock valued at $319,000 after buying an additional 1,258 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Read More
- Five stocks we like better than Phreesia
- How to Read Stock Charts for Beginners
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Health Care Stocks Explained: Why You Might Want to Invest
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What is an Earnings Surprise?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.